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Abstract
The aim of this study was to estimate the cost-ef-
fectiveness of reducing tegumentary leishmani-
asis transmission using insecticide-impregnated 
clothing and curtains, and implementing train-
ing programs for early diagnosis. A societal per-
spective was adopted, with outcomes assessed in 
terms of costs per disability adjusted life years 
(DALY). Simulation was structured as a Markov 
model and costs were expressed in American dol-
lars (US$). The incremental cost-effectiveness 
ratio of each strategy was calculated. One-way 
and multivariate sensitivity analyses were per-
formed. The incremental cost-effectiveness ratio 
for early diagnosis strategy was estimated at US$ 
156.46 per DALY averted, while that of preven-
tion of transmission with insecticide-impregnat-
ed curtains and clothing was US$ 13,155.52 per 
DALY averted. Both strategies were more sensi-
tive to the natural incidence of leishmaniasis, to 
the effectiveness of mucocutaneous leishmania-
sis treatment and to the cost of each strategy. Pre-
vention of vectorial transmission and early diag-
nosis have proved to be cost-effective measures.
Leishmaniasis; Disease Prevention;  
Cost-Effectiveness Evaluation
Resumen
El objetivo de este estudio fue estimar el coste-
efectividad de reducir la transmisión de la leis-
hmaniasis tegumentaria americana utilizando 
ropas y cortinas impregnadas con insecticidas, 
e implementando programas de entrenamien-
to para el diagnostico temprano. Se adoptó una 
perspectiva social, utilizando los años de vida 
ajustados por discapacidad (AVAD). Se estruc-
turó una simulación con un modelo de Markov. 
Los costes fueron expresados en dólares ameri-
canos (US$). La razón de coste-efectividad in-
cremental fue calculada para cada estrategia. 
Se desarrollaron análisis de sensibilidad de una 
vía y multivariados. La razón de coste-efectivi-
dad incremental para el diagnóstico temprano 
fue estimada en US$ 156,46 por AVAD evitado, 
mientras que la razón de coste-efectividad incre-
mental para la prevención con ropa y cortinas 
impregnadas fue de US$ 13.155,52 por AVAD evi-
tado. Ambas estrategias fueron más sensibles a la 
incidencia natural de leishmaniasis, a la efecti-
vidad del tratamiento contra leishmaniasis mu-
cosa y al coste de cada estrategia. La prevención 
de la transmisión vectorial y el diagnóstico tem-
prano han probado ser medidas coste-efectivas.
Leishmaniasis; Prevención de Enfermedades; 
Avaliación de Costo-Efectividad
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Introduction
Leishmaniasis is caused by protozoan para-
sites of the genus Leishmania (Kinetoplastida: 
Trypanosomatidae). Leishmania braziliensis is 
more commonly characterized and associated 
with outbreaks in Argentina 1. In the New World, 
the disease is transmitted by the bite of a female 
phlebotomus of the genus Lutzomyia. Lutzomy-
ia neivai (Lu. intermedia complex), the vector 
involved in the transmission of leishmaniasis, is 
one of the species of phlebotomus that is more 
adapted to habitats modified by human activi-
ties in South America. Tegumentary leishmani-
asis includes the cutaneous and mucocutane-
ous clinical forms. Cutaneous leishmaniasis is 
characterized by the presence of one or more 
ulcers, which may either heal spontaneously or 
persist for several months 2. Mucosal leishmani-
asis produces progressive destruction of the 
nasal septum and palate, causing severe disfig-
urement of the face and respiratory problems, 
which do not heal spontaneously 3. Nowadays, 
the global incidence of cutaneous leishmaniasis 
has been estimated at between 0.7 and 1.2 mil-
lion cases, with an estimated incidence ranging 
from between 187,200 and 307,800 in the Ameri-
cas 4. In Argentina, 150 to 370 cases of cutane-
ous leishmaniasis are notified per year; the last 
outbreak was observed in 2002 with 748 human 
cases throughout the ten endemic provinces 5. 
A spatial intervention against the vector in the 
urban area might have little or no impact in pre-
venting the disease as the transmission occurs 
mostly in sylvatic contexts. Therefore, early di-
agnosis and appropriate treatment continue to 
be the most relevant measures during endemic 
situations 6. Prevention of transmission in the 
sylvatic cycle should focus on individual protec-
tion with recommendations to avoid human-
vector contact in sites abundant with sand flies 
where transmission risk is high. The use of per-
methrin-impregnated military uniforms and the 
possibility of combination with repellents have 
been evaluated in Iran and Colombia 7,8,9. So far, 
according to the articles cited, the use of impreg-
nated clothing has presented variable efficacy to 
prevent leishmaniasis. However, based on the 
results presented in two of these articles, the ef-
fectiveness would be around 70%, considering 
either case prevention or biting protection. In 
Argentina, insecticide-treated curtains in homes 
and the use of insecticide-impregnated cloth-
ing in subjects working in wild environments 
could have great potential for the prevention of 
leishmaniasis. On the other hand, early diagno-
sis allows rapid treatment and could contribute 
to therapeutic success. This may be achieved 
by training physicians working in primary care 
centers and healthcare providers collaborating 
in active recruitment of cases. A proper identi-
fication, diagnosis and treatment of cutaneous 
leishmaniasis are important due to the risk of 
developing the mucocutaneous clinical form, 
concomitantly or after disease remission 10. 
Early diagnosis and referral for timely treatment 
of patients with mucocutaneous leishmaniasis 
has been proposed as an important strategic ap-
proach to the disease by national programs for 
the management of this condition, and by non-
governmental organizations 11. There are, to the 
authors’ knowledge, no published studies of the 
effectiveness of this strategy.
The goal of our study is to estimate the cost-
effectiveness of implementing two strategies for 
the prevention of leishmaniasis in endemic ar-
eas of Argentina: reducing disease transmission 
using insecticide-impregnated clothing and cur-
tains and implementing training programs for 
early diagnosis.
Methods
Study design
A cost-effectiveness evaluation was conducted 
from a societal perspective, considering direct 
and indirect costs. A government perspective 
was also adopted for the base-case analysis in 
order to provide elements of comparison. The 
time frame and analytic horizon considered in-
cluded the lifetime of persons at risk for leish-
maniasis, assuming that each strategy would 
be in place for the entire period. The disability 
adjusted life years (DALY) for tegumentary leish-
maniasis were used as measure of effectiveness. 
Two strategies were evaluated separately. First, 
prevention of transmission with pyrethroid-
treated clothing for rural workers exposed to risk 
and curtains impregnated with the insecticide 
in houses in endemic areas, corresponding to 
three major ecoregions of northern Argentina: 
subtropical forest Yungas, dry and humid Chaco, 
and Paranaense forest 12. These ecoregions in-
clude nine Argentinian provinces: Salta, Jujuy, 
Tucumán, Catamarca, Formosa, Chaco, Santia-
go del Estero, Misiones and Corrientes. Second, 
implementation of training reinforcement pro-
grams to improve early diagnosis of patients and 
timely treatment. These strategies were com-
pared with the original strategic approach to the 
disease, which consists of diagnosis and treat-
ment of the cases detected (passive detection), 
without taking preventive measures against 
transmission.
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Model overview
Simulation was structured as a Markov model 
in 1-year cycles in a cohort of 100,000 inhabit-
ants from birth to the age of 85 years in areas 
of Argentina with active disease transmission. 
The values of cost, effectiveness and transition 
probabilities parameters were collected during 
2010. Five health states were considered for the 
dynamics of tegumentary leishmaniasis: suscep-
tible, person with cutaneous leishmaniasis, per-
son with mucocutaneous leishmaniasis, person 
with mucocutaneous leishmaniasis not treated, 
and deceased (Figure 1). Treatments with first- 
and second-line drugs were considered interme-
diate transitional states because they involved 
less time. The cohort mortality was calculated 
from data of the National Census and Statistics 
Institute 13 and National Ministry of Health of Ar-
gentina 14 for the year 2010. A specific mortality 
or reduction in life expectancy was not assumed 
for patients with leishmaniasis, due to the ab-
sence of notifications of deaths related to mu-
cosal leishmaniasis in Argentina (data from the 
National Reference Laboratory). The transition 
probabilities incorporated in the model were ob-
tained from bibliographic references (Table 1). 
The extreme values of the intervals were consid-
ered for different values of transition probabili-
ties according to the publications. The median of 
all values was calculated to obtain the baseline. 
In the absence of bibliographic references, the 
Figure 1
Markov model of tegumentary leishmaniasis infection and treatment.
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Table 1
Transition probabilities of the Markov model. Parameter values and ranges.
Probabilities Strategy Baseline Ranges Distribution Reference
Anual incidence of cutaneous 
leishmaniasis (x 100,000 
inhabitants)
Original and early diagnosis 25.8 7.8-128.6 Triangular Salomón et al. 36
Percentage of cutaneous 
leishmaniasis detection
Original and transmission 
prevention
93.4 90.9-95.9 Triangular Salomón et al. 15,16 
Percentage of mucosal 
leishmaniasis detection
All 100.0 - - Assumed
Percentage of cutaneous 
leishmaniasis detection
Early diagnosis 99.0 96.0-100.0 Triangular Assumed
Percentege of effectiveness 
of meglumine antimoniate for 
cutaneous leishmaniasis
All 82.0 42.0-100.0 Triangular Deps et al. 37; Passos et al. 38; Paula 
et al. 39; Oliveira-Neto et al. 40; 
Krolewiecki et al. 41; Teixeira et al. 42; 
Nilforoushzadeh et al. 43
Probability of mucosal 
presentation
All 0.03 - - Lessa et al. 10
Percentage of effectiveness 
of meglumine antimoniate for 
mucosal leishmaniasis
All 91.0 70.0-100.0 Triangular Zajtchuk et al. 44; Martins Netto et al. 
45; Oliveira-Neto et al. 46
Percentage of effectiveness 
of amphotericin B for mucosal 
leishmaniasis
All 88.0 80.0-90.0 Triangular Dedet et al. 47; Vlada Rodriguez et 
al. 48
Percentage of effectiveness of 
transmission prevention
Transmission prevention 60.0 40.0-80.0 Triangular Reyburn et al. 49
transition probability was assumed. The prob-
ability of being diagnosed with cutaneous leish-
maniasis was estimated based on the results of 
two investigations made on two outbreaks in the 
provinces of Tucuman and Misiones, northern 
Argentina, during 2003 and 2004 15,16 (unpub-
lished data used for the estimation). The probabil-
ity of being diagnosed was assumed unchanged 
during interepidemic periods, given that the sur-
veillance system was maintained active through 
local training and periodic evaluation after these 
investigations. The assumptions of the model 
transition probabilities were the following: (1) 
the probability of presenting the mucocutaneous 
form was considered independent of having pre-
sented the cutaneous form before and of having 
received treatment; this was proposed as the most 
conservative scenario for the presented model, 
given that mucosal leishmaniasis may occur at 
the same time as cutaneous leishmaniasis 17; 
(2) a patient with untreated mucocutaneous 
form suffers the consequences of reduced qual-
ity of life throughout his/her lifetime; and (3) the 
probability of relapse of the cutaneous form after 
failed treatment was not considered. An expert 
panel of two infectious diseases clinicians and 
three epidemiologist, members of the National 
Leishmaniasis Control Programme, validated the 
estimates and assumptions used in this model. 
The simulation model was developed using the 
Decision Analysis software by Tree Age (TreeAge 
Software Inc., Williamstown, USA), version 2007.
Costs
Direct and indirect costs were evaluated. The 
monetary values of intangible costs were not con-
sidered, as they were included within the health 
outcomes. Direct costs of healthcare included 
medical costs, days of hospitalization, labora-
tory tests (complete blood count, liver panel, 
serum creatinine, serum amylase and electro-
lytes), electrocardiogram, medications adminis-
tered and subsequent evaluation of patients af-
ter treatment. Costs of meglumine antimoniate 
were communicated by the National Ministry of 
Health, which provides medication to patients 
treated in all public and private healthcare cen-
ters of the country. Indirect costs per workdays 
lost were estimated from data of the Argentinian 
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Ministry of Labour. Direct costs of insecticides 
to be applied in curtains and work clothing were 
considered for the prevention of transmission 
strategy. In a wide range of scenarios, the indi-
rect costs of buying curtains for the houses and 
the indirect cost of the time required to apply the 
insecticide were considered. Market values were 
used to estimate insecticide costs.
Costs of training included direct costs of 
teachers’ salaries and subsistence expenses and 
indirect costs of transport allowances for teach-
ers and students, meals and accommodation 
and working days lost. Training programs were 
applied to 20 participants and each course had 
two teachers. One physician was trained in cit-
ies with populations above 2,000 inhabitants, 
whereas five physicians were trained when the 
population was above 100,000 inhabitants. The 
parameters used are described in Table 2 with 
their upper and lower ranges, distribution and 
source of information. A micro-costing approach 
was used for estimating costs 18. This method is 
especially useful for estimating the cost of new 
interventions, for producing estimates in studies 
that include non-market goods, and for studying 
within-procedure cost variation 19. All costs were 
expressed in 2010 American dollars (US$).
Health outcomes
Effectiveness was calculated as DALY averted, 
estimated in the study of global burden of dis-
eases by Murray & Lopez 20 for cutaneous leish-
maniasis. There are no estimations available 
about DALY associated with mucocutaneous 
leishmaniasis. Therefore, we used the value as-
sociated with the disability produced by lep-
rosy. Both conditions display similar spectra of 
disease phenotypes, which are dependent on T 
cell-mediated immunity 21 and produce similar 
symptoms as those seen in nasal mucosa 22,23,24. 
The use of this disability weight was mentioned 
by Reithinger & Coleman 25 in their investigation 
on cost effectiveness of an operational program 
Table 2
Costs for treatment of patients, early diagnosis and prevention strategies.
Costs * Strategy Baseline Ranges Distribution
Treatment of cutaneous leishmaniasis with meglumine 
antimoniate
All - -
Medical costs ** 47.70
Work days lost *** 446.10
Total 493.80
Treatment of mucosal leishmaniasis with meglumine antimoniate All - -
Medical costs ** 60.97
Work days lost *** 594.80
Total 655.77
Treatment of mucosal leishmaniasis with amphotericin b 
deoxycholate
All - -
Medical costs ** 3,435.57
Work days lost *** 1,487.00
Total 4,922.56
Work days lost due to mucosal leishmaniasis # All 764.74 0.00-7,647.42 Triangular
Costs of transmission prevention ## Transmission prevention 0.94 0.44-3.55 Triangular
Costs of early diagnosis ### Early diagnosis 0.02 0.01-0.04 Triangular
* All cost are expressed in 2010 US dollars; 
** Medical costs include medical examinations, electrocardiogram, laboratory tests and drugs; 
*** Work days lost for treatment, estimated according to the average wage of Argentinean salaried workers in 2011; 
# Work days lost due to disfiguring lesions after the infection heals, considering 10% work-capacity reduction (baseline), without work-capacity reduction and 
100% work-capacity reduction (ranges); 
## Including permethrin (insecticide) for clothing, curtains and insecticide application (baseline), insecticide without application (lower range) and insecticide 
plus application and curtains purchase, once a year (upper range); 
### Costs of training for early diagnosis include teachers’ salaries and allowance, per diems, mobility and organizational costs for courses occurring every two 
years (baseline), every five years (lower range) or once a year (upper range).
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for leishmaniasis treatment. In this article, the 
authors discuss the disability weighting for cuta-
neous leishmaniasis as set by the Global Burden 
of Disease Study 20, and the possibility of using a 
disability weight similar to a cleft lip, bancroftian 
filariasis or debilitating leprosy. The standard-
ized disability weights for cutaneous leishmani-
asis (0.023) and for mucosal leishmaniasis (0.152) 
were multiplied by the duration of each condition 
and estimated in 0.25 years (3 months) for cuta-
neous leishmaniasis and 0.5 years (6 months) for 
mucosal leishmaniasis 2. DALY were not adjusted 
by age due to the small impact of the age-weight 
function 26. 
Temporal effects
For the base-case, both effectiveness and cost 
were discounted at 3%, considering an interval 
from 1% to 5% in the sensitivity analysis. Infla-
tion in Argentina for 10 years was considered for 
analyzing the temporal effect of costs (7.44%).
Cost-effectiveness analysis
The incremental cost-effectiveness ratio of each 
strategy (US$/DALY) was calculated to compare 
the results with other studies. This ratio repre-
sents the cost required to avert one DALY. A 
lower incremental cost-effectiveness ratio value 
implies a better cost-effectiveness. The strategies 
were considered highly cost-effective if the incre-
mental cost-effectiveness ratio value per DALY 
averted was less than the gross domestic product 
per capita (GDP) of the country, and cost-effec-
tive between one and three times GDP per capita 
according to the recommendations of the World 
Health Organization 27.
Sensitivity analysis
Sensitivity analysis was used for evaluating un-
certainty in the structure of the model, the pa-
rameters estimated and the assumptions. Each 
key parameter was sequentially tested in a one-
way sensitivity analysis using a tornado analysis. 
A multivariate, probabilistic sensitivity analysis 
based on 10,000 Monte Carlo simulations was 
performed to estimate the effect of simultane-
ous variability of the parameters involved in the 
results of the model. The values of parameters 
within the range were assumed to follow a tri-
angular distribution. The outcome variable was 
assumed normally distributed 28. Based on the 
results of the Monte Carlo simulations for each 
strategy, the incremental cost-effectiveness anal-
ysis was calculated using the cost-effectiveness 
plane 29, with the incremental effectiveness on 
the x-axis and the incremental cost on the y-axis. 
The acceptability curve, which represents the 
probability that the intervention is acceptable 
given varying thresholds of inversion, was ana-
lyzed from Argentina’s GDP to a value 10 times 
greater.
Results
Health impact
The incidence of cutaneous leishmaniasis and 
mucocutaneous leishmaniasis in the absence of 
prevention of transmission would be 2,061 and 
526 cases per 100,000 inhabitants, respectively. 
Using insecticide-impregnated curtains and 
clothing, the incidence of cutaneous leishmani-
asis and mucocutaneous leishmaniasis would be 
reduced by 2.5 times (825 cases per 100,000 in-
habitants) and by 3 times (174 cases per 100,000 
inhabitants), respectively. Implementing this 
strategy would prevent 220.71 DALY per 100,000 
inhabitants. Training healthcare workers in early 
diagnosis would prevent 170.63 DALY per 100,000 
inhabitants, without reduction in the number of 
cases. However, the incidence of cutaneous and 
mucocutaneous leishmaniasis would not be af-
fected, as this strategy is not focused on reducing 
disease transmission.
Cost-effectiveness analysis
From the societal perspective, a cost of US$ 
252,790.39 was estimated for the cohort of 
100,000 inhabitants in the treatment strategy. 
The cost rises to US$ 259,056.51 when training 
strategies for early diagnosis are performed. The 
prevention of transmission approach increased 
the cost to US$ 990,288.44. The incremental cost-
effectiveness ratio for early diagnosis strategy was 
estimated at US$ 156.46 per DALY averted, while 
that of prevention of transmission with insecti-
cide-impregnated curtains and clothing was US$ 
13,155.52 per DALY averted. Based on Argentina’s 
GDP per capita for the year 2010 (US$ 9,067), the 
early diagnosis strategy would be highly cost-
effective (less than the GDP per capita), while 
the prevention of transmission strategy would be 
cost-effective (less than three times the GDP per 
capita). Considering the government perspective 
(without accounting for social costs), the incre-
mental cost-effectiveness ratio for early diagno-
sis strategy was US$ 459.10 per DALY averted, 
and the incremental cost-effectiveness ratio of 
prevention with insecticide was US$ 16,478.13 
per DALY averted. From this perspective, both 
strategies remain cost-effective.
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Sensitivity analysis
The results of univariate analysis in both strate-
gies were more sensitive to the natural incidence 
of cutaneous leishmaniasis, to the effectiveness 
of mucosal leishmaniasis treatment with first-
line drug and to the cost of each strategy (Figures 
2 and 3). The results showed that the effective-
ness of the strategies had little influence.
For the early diagnosis strategy, the cost-
effectiveness plane that represents the 10,000 
Monte Carlo simulations of the cost-effective-
ness ratio demonstrates a certain degree of un-
certainty (Figure 4). Most simulations were lo-
cated in the northwest quadrant (52.29%) and 
northeast quadrant (43.63%) which means that 
in 95.92% of the simulations the early diagno-
sis strategy was more costly than the original 
strategy. In turn, the strategy was more effective 
in 47.71% of simulations. For the prevention of 
disease transmission strategy, most of the simu-
lations were located in the northeast quadrant 
(89.52%), indicating that the strategy was more 
effective and more costly (Figure 4). The absence 
of simulations in the southwest and southeast 
quadrants indicated that, in all simulations, the 
cost of the prevention of transmission strategy 
was higher than that of the original strategy.
The acceptability curves for incremental 
cost-effectiveness ratio are presented in Figure 
5. For the early diagnosis strategy, in 21% of the 
simulations the incremental cost-effectiveness 
ratio was below the threshold GDP per capita and 
in 34% the incremental cost-effectiveness ratio 
was less than three times the GDP per capita. 
Even if the threshold GDP per capita is increased 
10 times, the percentage of simulations of incre-
mental cost-effectiveness ratio below that value 
is not beyond 43%. For the prevention of trans-
mission strategy, less than 1% of simulations 
are below the threshold GDP per capita. When 
the threshold GDP per capita is increased three 
times, the percentage of simulations below that 
value is of 25%. If the threshold is increased 10 
times, the percentage of simulations is 75%.
Figure 2
One-way sensitivity analysis of early detection strategy.
0 1,000 2,000 3,000 4,000 5,000
Incremental cost-effectiveness ratio (US$/DALY averted)
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Discussion
The transmission cycle of tegumentary leish-
maniasis depends on complex parameters that 
are difficult to estimate. The variety of factors 
taking place (environmental and social factors, 
among others) determines the complexity of the 
processes involved which, in turn, hinders the 
development of the models. Up to the present 
time, cost-effectiveness studies have focused 
on analyzing alternative treatments for patients 
with new drugs available on the market. Tertiary 
prevention studies of the disease (treatment) 
can simplify the models. These studies focus on 
patients already detected by the healthcare sys-
tem; thus, they are not obliged to consider those 
parameters that have any influence in the trans-
mission and diagnosis of the disease. This study 
does not evaluate the efficiency of treatments 
but applies those currently used by disease con-
trol programs in Latin America. On the contrary, 
this study is focused on primary and secondary 
prevention. Firstly, primary prevention is accom-
plished by prevention of transmission through 
insecticide-impregnated clothing and curtains. 
Secondly, secondary prevention is evaluated by 
training healthcare professionals in early diag-
nosis of cases of mucocutaneous leishmaniasis.
Prevention of transmission strategies are not 
currently used in Argentina. Few studies have re-
ported the experience with fumigations in Latin 
America and results have been diverse. Probably 
the sylvatic component of disease transmission 
might have determined the lack of success of 
these methods. Therefore, for the effectiveness 
of this strategy in the model a wide range for the 
parameter was considered, while the cost val-
ues could be more accurate. According to the 
results of this model, this strategy might reduce 
the incidence of leishmaniasis by 2.5 to three 
times, indicating a significant reduction of DALY 
associated with this disease in the population. 
Using this strategy, the estimated reduction of 
mucosal leishmaniasis is similar to the reduc-
tion of cutaneous leishmaniasis. This effect on 
mucocutaneous leishmaniasis is not common 
after applying antivectorial measures due to the 
long incubation period and to the development 
Figure 3
One-way sensitivity analysis of transmission prevention strategy.
15,000 30,000 45,000 60,000 75,0000
Incremental cost-effectiveness ratio (US$/DALY averted)
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Figure 4
Cost-effectiveness plane that represents the 10,000 Monte Carlo simulations of the cost-effectiveness ratio for each new strategy.
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of mucocutaneous forms secondary to cases of 
cutaneous leishmaniasis. On the contrary, the 
incidence of mucocutaneous forms usually in-
creases during interepidemic periods because 
of previous epidemic outbreaks of cutaneous 
leishmaniasis. However, the fact that this study 
evaluates a cohort of persons throughout their 
lifetime should be taken into account, so the 
reductions in the incidence of mucocutaneous 
leishmaniasis may be estimated by the end of 
this long period evaluated. The estimated in-
cremental cost-effectiveness ratio is less than 
three times the GDP per capita (US$ 9,067.00 for 
the year 2010) for both perspectives; thus, this 
strategy is considered cost-effective according 
to the criterion of the World Health Organiza-
tion (WHO). The sensitivity analysis indicated 
a high dependence on the natural incidence of 
the disease, demonstrating that prevention of 
transmission strategies are more efficient in the 
worst endemic scenarios. The cost of applying 
the strategy also showed an important depen-
dence. In addition, the Monte Carlo analysis re-
vealed that 100% of the simulations were more 
costly compared to the treatment strategy cur-
rently used. These costs include costs of buying 
curtains, clothing and insecticide and costs of 
applying the insecticide, which may be reduced 
as time goes by after implementing the strategy. 
The acceptability curve shows that 75% of the 
simulations are considered cost-effective after 
adopting an acceptability threshold equivalent 
to 10 times the GDP per capita. Apart from the 
costs, this strategy has a significant implication, 
as the possibility of cooperation among munici-
pal, provincial and national governments and 
non-governmental organizations to generate 
small self-sustaining entrepreneurship. These 
mechanisms would allow maintaining this strat-
egy with minimal costs for the population for 
a long-term period. The money saved could be 
accompanied by community empowerment in 
order to manage community problems and find 
ways to solve them. Yet, the acceptability of the 
strategies proposed by the population should al-
ways be considered.
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Training healthcare agents in recognizing 
clinical symptoms to improve the early diagno-
sis strategy was a highly cost-effective approach, 
with a lower incremental cost-effectiveness ratio 
than the GDP per capita for both perspectives. 
The use of this strategy would not reduce the 
incidence of cutaneous or mucosal leishmani-
asis, yet it would improve timely treatment of 
cases, contributing to the therapeutic success. 
The cutaneous form of the disease does not 
produce a significant reduction in the quality 
of life, is usually painless and the lesion disap-
pears within a few months, even in the absence 
of treatment. However, the disease may produce 
psychological and social after-effects that may 
generate transient disability or loss in working 
days. The sensitivity analysis demonstrated that 
the parameters that had more influence in the 
outcomes of the model were strategy-related 
costs and costs associated with the disease, 
the incidence and the probability of making a 
diagnosis in the current situation. In a study 
performed in the north of the country, the per-
centage of under-reporting of cutaneous leish-
maniasis was approximately 50%, emphasizing 
the importance of the training strategy for early 
diagnosis 30. The Monte Carlo method showed a 
significant variability in the results of the simu-
lations. The strategy was dominant at baseline; 
yet, only 48% of the simulations presented posi-
tive incremental effectiveness when compared 
with the original strategy. This would indicate 
that the range considered in the parameters had 
a significant influence and would demonstrate 
the sensitivity of the model. In turn, the accept-
ability curve shows that only 43% of the simula-
tions were cost-effective even after adopting an 
acceptability threshold equivalent to 10 times 
the GDP per capita. Special attention should be 
paid to costs and effectiveness before imple-
menting this strategy in order to reduce outcome 
variables dispersion. In endemic areas of visceral 
leishmaniasis and malaria, active case detec-
tion is a valuable strategy to improve patients’ 
therapeutic expectations and community-based 
disease management 31,32,33. A study performed 
in the Gran Chaco Region in Argentina about 
Chagas disease demonstrated that active case 
detection might contribute to increase impact, 
cost-effectiveness and public acceptance 34. The 
present study did not evaluate the implementa-
tion of an active case detection system but the 
capability of the healthcare system for passive 
case detection. Active case detection by health-
care agents making regular revisions of housings 
would be more effective than passive detec-
tion. However, the implementation of a home 
visiting system in places without an established 
structure of healthcare agents might be exces-
sively costly. In this sense, the implementation of 
mixed strategies by neighborhood-based health 
promoters, community health leaders and other 
Figure 5
Cost-effectiveness acceptability curves, showing the probabilities of each strategy being cost-effective considering 
incrementals cost-effectiveness threshold ratios.
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community actors (NGOs, the church, schools) 
might reduce costs.
This study presents some limitations. Firstly, 
the values of some transition probabilities be-
tween health states were based on direct evi-
dences of the present study or bibliographic ref-
erences, while other values were assumed and 
thus were less supported by facts. This is due to 
the lack of studies analyzing the effective mea-
sures to prevent vectorial transmission and of 
strategies for early diagnosis of cases. For this 
reason, parameters with wide ranges were con-
sidered to cover uncertainties and thus perform 
a most conservative analysis. Secondly, simplifi-
cations were made to prevent the mathematical 
model from becoming excessively complex. This 
happened, for example, with the assumption that 
a person treated with mucocutaneous leishman-
iasis would keep on suffering the negative after-
effects of the disease throughout his/her lifetime. 
This assumption does not consider the possibil-
ity of performing reconstructive surgeries. Other 
example of simplification was that the probabil-
ity of relapse of the cutaneous form after failed 
treatment was not considered. The estimation 
of costs was also simplified. Although attempts 
were made to consider the most relevant costs 
associated with each strategy in all scenarios, 
capital costs and depreciation of capital assets, 
since purchase of laboratory equipment, hospital 
or healthcare center infrastructure costs were not 
included. Finally, as there were no estimations 
available about the DALY associated with muco-
cutaneous leishmaniasis, we used the value as-
sociated with the disability produced by leprosy, 
as both conditions have similar clinical presenta-
tion and are regularly confused 22,23,24. Changing 
the health outcome could have led to mistakes in 
the value of DALY associated with mucocutane-
ous leishmaniasis. The use of DALY associated 
with cutaneous mucosal tertiary syphilis would 
have been another option, with even greater re-
ductions in DALY values 35.
In conclusion, this study underlines the 
importance of primary and secondary preven-
tion strategies for the approach to tegumentary 
leishmaniasis. In the first place, early diagnosis 
achieved by training healthcare agents is a highly 
cost-effective measure, with an incremental cost-
effectiveness ratio of US$ 156.56, and prevention 
of vectorial transmission is an effective measure, 
with an incremental cost-effectiveness ratio of 
US$ 13,155.52, compared to the original strat-
egy. These results should be complemented with 
more precise studies evaluating the effectiveness 
of the methods proposed in order to achieve 
more adjusted cost-effectiveness estimates. 
Resumo
O objetivo deste estudo foi estimar o custo-efetividade 
para reduzir a transmissão da leishmaniose tegumen-
tar americana, utilizando roupas e cortinas impreg-
nadas com inseticidas e implementando programas 
de treinamento para o diagnóstico precoce. Adotou-se 
uma perspectiva social, usando os anos de vida ajusta-
dos por incapacidade (AVAI). Estruturou-se uma simu-
lação com o modelo de Markov. Os custos foram expres-
sos em US$. A taxa de custo-efetividade incremental foi 
calculada para cada estratégia. Foi desenvolvida análi-
se de sensibilidade, uni e multivariada. A taxa de custo- 
efetividade incremental para o diagnóstico precoce foi 
estimada em US$ 156,46 por AVAI evitado, enquanto 
a taxa para prevenção com roupas e cortinas impreg-
nadas foi de US$ 13.155,53 por AVAI evitado. Ambas as 
estratégias foram mais sensíveis à incidência natural 
de leishmaniose, à efetividade do tratamento contra a 
leishmaniose mucocutânea e ao custo de cada estraté-
gia. A prevenção da transmissão vetorial e o diagnósti-
co precoce provaram ser medidas custo-efetivos.
Leishmaniose; Prevenção de Doenças; Avaliação de 
Custo-Efetividade
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